Vor Biopharma Inc. (VOR)
After hours:
| Previous Close | 1.7200 |
| Open | 1.6700 |
| Bid | 1.7500 x 400 |
| Ask | 1.7800 x 300 |
| Day's Range | 1.6700 - 1.8000 |
| 52 Week Range | 1.6200 - 5.7000 |
| Volume | |
| Avg. Volume | 337,877 |
| Market Cap | 120.742M |
| Beta (5Y Monthly) | -0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update. “We are very pleased w
- GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 4,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 6,375 shares of Vor Bio’s common stock to two newly hired employees. The foregoing stock
- GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Barclays 26th Annual Global Healthcare ConferenceFireside Chat: Tuesday, March 12, 2024 at 4:35 pm ET Location: Miami, FL A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. H.C. Wainwright 2nd Annual Cell Therapy V
